ADC Programs
IKS012
FOLR1-directed ADC in preclinical development for ovarian cancer.
IKS012 has been designed to provide a FOLR1-directed therapy with raised TI over in-clinic and on-market competitors - resulting from tumor-selective enzymatic release of an auristatin payload.
In preclinical studies, it is associated with high anti-cancer activity in FOLR1-high xenograft models and class-leading toxicity profile with a HNSTD in non-human primates that is significantly higher than all other FOLR1-directed ADCs.
Iksuda deepens clinical pipeline
Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets
Forging stable relationships for Antibody-Drug Conjugates
DCs are a class of biopharmaceuticals that target cancer cells while leaving healthy cells alone.
Keep informed
Sign up for our latest programme news and insights
